Convalescent plasma therapy did not show benefit in reducing mortality risk among COVID-19 patients, according to an interim analysis of a randomised controlled trial done at AIIMS in Delhi to assess the efficacy of this mode of treatment, a PTI news agency report stated.
The therapy involves taking antibodies from the blood of a person who has recovered from COVID-19 and transfusing those into an active coronavirus infected patient to help kickstart the immune system to fight back the infection.
AIIMS Director Dr Randeep Guleria told on Thursday no clear mortality benefit of convalescent plasma therapy was seen during a trial conducted among 30 COVID-19 patients.
During the trial, one group of patients was given convalescent plasma therapy along with the standard supportive treatment while the other group only received standard treatment. The number of fatalities recorded in both the groups was equal and there was not much clinical improvement in the condition of patients, he said.
"However, this is just an interim analysis and we need to do a more detailed evaluation to see if any sub-group may benefit from plasma therapy," Dr Guleria said.
He also underlined that plasma has to be tested for its safety and should have sufficient antibody to be useful to COVID-19 patients.
